| HOME >> MEDICINE >> TECHNOLOGY |
MAHWAH, N.J., Oct. 13, 2011 /PRNewswire/ -- Heartland Bridge Capital, Inc. (OTCBB:HLBC), a private equity firm focused on developing a portfolio of unique investments in emerging technologies, announced that it has made its initial funding of $100,000 in biotechnology company HepatoChem, Inc., pursuant to a definitive investment agreement to provide up to $400,000 of equity capital.
Headquartered in Cambridge, MA, HepatoChem is a privately held company that offers pharmaceutical and biotech companies a reliable and efficient means of accessing small molecule metabolites in quantities needed in the drug development process. HepatoChem's innovative technology uses biomimetic catalysts to mimic the metabolic function of the liver. This unique technology, developed in collaboration with Professor John Groves at Princeton University, enables the production of metabolites more quickly and with greater cost-effectiveness than any other technology currently available.
James F. Groelinger, the CEO of Heartland Bridge Capital, commented: "We are very excited to be an early investor supporting the commercial development of HepatoChem's extraordinarily innovative technology that should significantly advance the process of commercializing new drugs. This first step in our relationship with HepatoChem could result in additional investment opportunities in important pharmaceutical developments, and we look forward to seeing this relationship grow into a key element in our overall life sciences portfolio."
Marc Bazin, HepatoChem's founder and CEO, said: "We are pleased to be the beneficiary of this agreement with Heartland Bridge Capital. This first round of financing validates the HepatoChem technology platform, which is a crucial step in the drug development process. This initial investment into our Company should enable the commercialization of our metabolite production technology, and we see this as an important first step in developing a long-term relationship with Heartland Bridge Capital and its team."
HLBC Investor Conference Call
The Company will be conducting an investor conference call tomorrow at 11:00am EDT to discuss this investment, and Heartland Bridge Capital's overall business strategy.
Date: Friday, October 14, 2011
Time: 11:00 a.m. (EDT)
Dial-in Number: (712) 432-0900
Passcode: 316914
It is recommended that participants phone-in 5 to 10 minutes prior to the start of the call.
Following the event, a replay of the conference call will be available by calling (712) 432-0990, and entering pass code 316914.
About HepatoChem, Inc
HepatoChem is a chemistry based technology platform company with a primary focus on metabolite production from bioactive small molecules. Founded by Marc Bazin, previously with Pfizer, Inc., and Prof. John T. Groves, the Hugh Stott Taylor Chair of Chemistry at Princeton University, HepatoChem is dedicated to developing technologies that help pharmaceutical companies improve the quality of drug development pipelines. HepatoChem offers a unique and powerful solution to resolve the lack of rapid and efficient metabolite access in drug discovery. www.hepatochem.com
About Heartland Bridge Capital, Inc.
Heartland Bridge Capital, Inc. (OTCBB:HLBC) is a public company that, in addition to managing its own operating entities, participates in emerging companies run by exceptionally talented entrepreneurs and operating executives who are dedicated to creating positive change in our world. HLBC will function as an owner, product developer, and investor focused primarily on providing equity, acquisition debt, or bridge financing to emerging high-growth companies and entrepreneurs in the areas of clean energy, waste management, life sciences, and digital document services. www.heartlandbridgecapital.com.
To request an investor packet on Heartland Bridge Capital register online at www.wallstreetnewscast.com/request/hlbc.html
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Heartland Bridge Capital, Inc. cautions that statements made in this news release relating to the investment in HepatoChem, and potential investment in and the business direction of the Company, constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management. Actual results could differ materially from current projections or implied results. Heartland Bridge Capital, Inc. undertakes no obligation to revise these statements following the date of this news release.
Contact:
Melissa Diaz,
Investor Relations Counsel
South Street Media
Phone: (347) 483-0121
Email: southstmedia@gmail.com
'/>"/>
| SOURCE Heartland Bridge Capital, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related medicine technology :
1. Express Scripts HealthBridge Pharma & Biotech to Provide Exclusive Specialty Pharmacy Services and Limited Distribution Services for Solesta®
2. Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundations 2011 M. Judah Folkman International Conference in Cambridge, Mass.
3. Medical Care Technologies Inc. Closes $200,000 Bridge Loan Financing for Kids Health Center
4. BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study
5. Clearbridge BioLoc Unveils Innovative Lab-on-Card Analysis Platform for Point-of-Care Testing at Worlds Largest Clinical Lab Conference
6. Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility
7. BridgePoint Medical Announced 510(k) Clearance for an Expanded Indication to Treat Coronary Chronic Total Occlusions
8. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
9. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
10. BridgePoint Medical Names Industry Veteran as Chief Executive Officer
11. BridgePoint Medical Closes $9.1 Million Series C Financing
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |